160 related articles for article (PubMed ID: 28541555)
21. Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group.
Giebel S; Sadus-Wojciechowska M; Halaburda K; Drozd-Sokolowska J; Wierzbowska A; Najda J; Mendrek W; Sobczyk-Kruszelnicka M; Nowicki M; Holowiecki J; Czerw T
Ann Hematol; 2016 Jan; 95(2):263-9. PubMed ID: 26611854
[TBL] [Abstract][Full Text] [Related]
22. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
23. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
Sugimoto M; Ito S; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Ashizawa M; Yamamoto C; Fujiwara S; Okazuka K; Hatano K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kako S; Kanda Y
Ann Hematol; 2016 Sep; 95(9):1513-9. PubMed ID: 27365141
[TBL] [Abstract][Full Text] [Related]
24. [Clinical study on high-dose etoposide with granulocyte colony-stimulating factor for mobilization of autologous peripheral blood stem cells in patients with hematologic malignancies].
Shen WY; Li JY; Hong M; Zhang R; Lu H; Liu P; Qian SX; Xu W; Qiu HX; Wu HX
Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):628-31. PubMed ID: 23134856
[TBL] [Abstract][Full Text] [Related]
25. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.
Musso M; Scalone R; Marcacci G; Lanza F; Di Renzo N; Cascavilla N; Di Bartolomeo P; Crescimanno A; Perrone T; Pinto A
Bone Marrow Transplant; 2010 Jul; 45(7):1147-53. PubMed ID: 19898504
[TBL] [Abstract][Full Text] [Related]
26. Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study.
Partanen A; Turunen A; Valtola J; Pyörälä M; Vasala K; Kuittinen O; Kuitunen H; Penttilä K; Keskinen L; Kuittinen T; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
Transfusion; 2021 Feb; 61(2):516-525. PubMed ID: 33245582
[TBL] [Abstract][Full Text] [Related]
27. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
[TBL] [Abstract][Full Text] [Related]
28. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
[TBL] [Abstract][Full Text] [Related]
29. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
[TBL] [Abstract][Full Text] [Related]
30. Higher efficacy of Etoposide + Cytarabine Plus Pegfilgrastim in poorly mobilizing Multiple Myeloma and lymphoma Patients.
Ye P; Pei R; Lian J; Chen D; Li S; Cheng Y; Li F; Yuan J; Chen Y; Lu Y
Cytotherapy; 2023 Aug; 25(8):885-890. PubMed ID: 37212754
[TBL] [Abstract][Full Text] [Related]
31. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma.
Kato J; Mori T; Yokoyama K; Tsukada Y; Ueda T; Shimizu T; Okamoto S
Bone Marrow Transplant; 2011 Jul; 46(7):923-8. PubMed ID: 20972471
[TBL] [Abstract][Full Text] [Related]
33. BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant.
Marchesi F; Capria S; Giannarelli D; Trisolini SM; Ansuinelli M; Caputo MD; Serrao A; Gumenyuk S; Renzi D; Pupo L; Palombi F; Provenzano I; Di Rocco A; Pisani F; Romano A; Spadea A; Papa E; Canfora M; Cantonetti M; Mengarelli A
Bone Marrow Transplant; 2018 Aug; 53(8):1051-1054. PubMed ID: 29440737
[No Abstract] [Full Text] [Related]
34. Autologous stem cell transplantation and stem cell mobilization kinetics in elderly patients with B cell non-Hodgkin lymphoma.
Dogu MH; Çagirgan S; Ocakci S; Kaya AH; Ilkkilic K; Sanli NM; Kahraman S; Eren R; Tekgunduz E; Hacioglu S; Kaynar L; Erkurt MA; Altuntas F
Transfus Apher Sci; 2017 Dec; 56(6):814-818. PubMed ID: 29153347
[TBL] [Abstract][Full Text] [Related]
35. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
36. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
[TBL] [Abstract][Full Text] [Related]
37. Remobilization of hematopoietic stem cells with high-dose methotrexate and cytarabine in patients with non-Hodgkin's lymphoma and multiple myeloma after failure to mobilize with chemotherapy and cytokines.
Park SJ; Yoon DH; Kim S; Lee K; Park JS; Jang S; Park CJ; Chi HS; Park CS; Huh J; Suh C
Transfusion; 2014 Mar; 54(3):509-15. PubMed ID: 23800093
[TBL] [Abstract][Full Text] [Related]
38. Chemomobilization with Etoposide is Highly Effective in Patients with Multiple Myeloma and Overcomes the Effects of Age and Prior Therapy.
Wood WA; Whitley J; Moore D; Sharf A; Irons R; Rao K; Serody J; Coghill J; Gabriel D; Shea T
Biol Blood Marrow Transplant; 2011 Jan; 17(1):141-6. PubMed ID: 20637882
[TBL] [Abstract][Full Text] [Related]
39. Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE.
Esbah O; Tekgündüz E; Şirinoğlu Demiriz I; Civriz Bozdağ S; Kaya A; Tetik A; Kayıkçı Ö; Durgun G; Kocubaba Ş; Altuntaş F
Turk J Haematol; 2016 Sep; 33(3):209-15. PubMed ID: 26377357
[TBL] [Abstract][Full Text] [Related]
40. High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
Tsang ES; Villa D; Loscocco F; Visani G; Power M; Guiducci B; Clissa C; Song K; Toze C; Abou Mourad Y; Sutherland H; Sanford D; Nantel SH; Sehn LH; Scott DW; Savage KJ; Connors JM; Gerrie AS; Isidori A
Bone Marrow Transplant; 2019 Mar; 54(3):481-484. PubMed ID: 30171222
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
